498. Prolonged Benefit From Systemic rAAV8 in a Canine Model of Myotubular Myopathy

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)33307-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

402. Gait Function in a Canine Model of X-Linked Myotubular Myopathy After Systemic Delivery of AAV8-MTM1

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

X-Linked Myotubular Myopathy-Abnormal Genitalia Syndrome

2020English

36. AAV-MTM1 Prolongs Survival and Rescues Severe Muscle Weakness in Mouse and Canine Models of X-Linked Myotubular Myopathy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

Frequency and Phenotype of Myotubular Myopathy Amongst Danish Patients With Congenital Myopathy Older Than 5 Years

Journal of Neuromuscular Diseases
Neurology
2015English

Comparison of Amiodarone and Lidocaine in a Prolonged Ventricular Fibrillation Canine Model

Heart
Cardiovascular MedicineCardiology
2012English

a Novel Intronic Mutation in MTM1 Detected by RNA Analysis in a Case of X-Linked Myotubular Myopathy

Neurology: Genetics
NeurologyGenetics
2017English

A Case of Canine Systemic Nocardiosis.

The Japanese Journal of Veterinary Science
1986English

Prolonged Benefit From Ipilimumab Correlates With Improved Outcomes From Subsequent Pembrolizumab

Cancer immunology research
Cancer ResearchImmunology
2016English

606. Restricting MTM1 Transgene Expression to Skeletal Muscle in AAV-Mediated Gene Therapy for Myotubular Myopathy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy